In theory, targeting CD27 can induce anti-tumor responses by either agonizing the effector cells or depleting the Tregs dependent on the level of expression on individual cell populations (91) similar to targeting other members of the TNFRSF. The gene discussed is CD27; the disease is neoplasm.